Search Results - EGA European Genome-Phenome Archive

Constit Genome Sequencing

WGS blood data (fastq raw read sequences) for French ICGC leiomyosarcoma cancer sequencing project, 67 samples representing 67 donors. Sequencing was performed on Illumina HiSeq. The libraries were then sequenced with a 2 x 100bp paired-end protocol to a minimum mean coverage of 30x.

Dataset EGAD00001003190

Leiomyosarcoma Cancer Genome Sequencing

WGS cancer data (fastq raw read sequences) for French ICGC leiomyosarcoma cancer sequencing project, 78 samples representing 67 donors. Sequencing was performed on Illumina HiSeq. The libraries were then sequenced with a 2 x 100bp paired-end protocol to a minimum mean coverage of 50x.

Dataset EGAD00001003191

TRACERx NSCLC, multiregion sequencing of the first 100 tumors

BACKGROUND TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODS Multiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTS Widespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis. CONCLUSIONS ITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype.

Dataset EGAD00001003206

There are 80 Brain cancer cases in this study and belong to GBM-CN project.

There are 80 Brain cancer cases （160 samples）in this study and belong to GBM-CN project.

Dataset EGAD00001003218

The molecular landscape of colorectal cancer reveals genetic mutations（5 cases）

We collected tumor samples and adjacent nomal mucosae from 5 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing.

Dataset EGAD00001003223

The molecular landscape of colorectal cancer reveals genetic mutations（17 cases）

We collected tumor samples and adjacent nomal mucosae from 17 patients with colorectal cancer in surgical operation from 2014 to 2016 in the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Research Institute of Surgery, Third Military Medical University (Chongqing, China). the qualified captured library of each sample was then loaded on Illumina HiSeq 2000 (Illumina, San Diego, CA) platforms and subjected to high-throughput sequencing.

Dataset EGAD00001003224

Batches 4-6 prostatectomy analysis

Whole Genome Sequencing Illumina HiSeq data from 111 men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy (target sequencing depth 50X) with matched blood control (target sequencing depth 30X). This data is from batches 4 to 6.

Dataset EGAD00001003225

7827 results for "canc*"

in 14.79 milliseconds.

Constit Genome Sequencing

Leiomyosarcoma Cancer Genome Sequencing

TRACERx NSCLC, multiregion sequencing of the first 100 tumors

There are 80 Brain cancer cases in this study and belong to GBM-CN project.

The molecular landscape of colorectal cancer reveals genetic mutations（5 cases）

The molecular landscape of colorectal cancer reveals genetic mutations（17 cases）

Batches 4-6 prostatectomy analysis

Global Anaplastic Thyroid Cancer Initiative

Global Anaplastic Thyroid Cancer Initiative

Genome and transcriptome sequence data from a breast cancer patient

Genome and transcriptome sequence data from a rectal adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic gastric adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma of unknown primary patient

Genome and transcriptome sequence data from a metastatic cholangiocarcinoma patient

Genome and transcriptome sequence data from a metastatic colon cancer patient

Genome and transcriptome sequence data from a metastatic colon cancer patient

Genome and transcriptome sequence data from a GI primary (prev breast cancer) patient

Genome and transcriptome sequence data from a metastatic fibrolamellar hepatocelluar carcinoma patient

Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient

Genome and transcriptome sequence data from a metastatic rectosigmoid adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic carcinoma of the lung patient

Genome and transcriptome sequence data from a metastatic pancreatic carcinoma patient

Genome and transcriptome sequence data from a adenocarcinoma of the lung patient

Genome and transcriptome sequence data from a metastatic breast cancer patient

Genome and transcriptome sequence data from a metastatic endocervical adenocarcinoma patient